Filing Summary
Registrant: Adagio Therapeutics, Inc. The request metadata identifies Invivyd, Inc., but the filing itself identifies Adagio Therapeutics, Inc. as the registrant.
Business Context and Reporting Period
This Form 8-K reports events occurring on or after November 19, 2021, with the report dated and signed November 22, 2021. The filing concerns board appointments, committee assignments, and a chief legal officer appointment announced through a Regulation FD press release.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics. It is not a financial-results filing.
Material Changes
- Ellen Marram was appointed as a Class I director, with a term expiring at the 2022 annual meeting.
- Redonda Miller, M.D., was appointed as a Class II director, with a term expiring at the 2023 annual meeting.
- Ms. Marram was appointed to the Nominating and Corporate Governance Committee.
- Dr. Miller was appointed to the Compensation Committee.
- A November 22, 2021 press release also announced Jill Andersen as the company’s chief legal officer.
Compensation, Outlook, and Risks
- Ms. Marram and Dr. Miller will receive standard non-employee director compensation under the company’s existing policy.
- Both directors executed the company’s standard indemnification agreement.
- The filing states there were no arrangements or understandings relating to their selection, no family relationships with other directors or executive officers, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
- The filing provides no financial guidance, operating outlook, contingencies, or specific risk updates.
Investor Verification Items
- Confirm the correct issuer: the filing names Adagio Therapeutics, Inc., while the request metadata names Invivyd, Inc.
- Review the furnished Exhibit 99.1 press release for additional details regarding the chief legal officer appointment.
- Verify the directors’ compensation arrangements in the company’s August 6, 2021 prospectus and applicable governance documents.
- Assess any subsequent filings for changes to board composition, executive leadership, or the company’s corporate name.